Organoid technology has emerged as one of the most groundbreaking and cutting-edge technologies in the biomedical field. It finds widespread applications in disease modeling, drug discovery and screening, companion diagnostics, cell therapy, regenerative medicine, and more.

MIP Discovery Ltd has closed a £7M Series A financing to drive commercialisation of its synthetic affinity reagents in cell and gene therapy.

London-based Vidac Pharma Holding plc reported that its Warburg effect blocker VDA-1275 increased efficacy of chemotherapeutics 1000-fold in human organoid cancer models for liver cancer.

In addition to classic aseptic manufacturing topics, the international GMP PharmaCongress and GMP Pharmatechnica Expo 2024 in Wiesbaden will also address global challenges with modern vaccines and novel drugs based on cell and gene therapies. The event thus offers a comprehensive programme for experts from pharmaceutical manufacturing, technology and quality assurance from industry, labs and authorities, as well as a platform for the direct exchange of knowledge and experience.

Multi-omics liquid biospy specialist Freenome Inc. has baged US$254m in a financing round led by Roche AG to fund early cancer detection in 6,200 patients using its AI-guided cancer detection platform.

New figures published by the industry association European Bioplastics suggest a sharp increase in the production of sustainable plastics in the next two years and calls for policy support.

Christine Lind will join Stockholm-based Bactiguard AB as new CEO at the Annual General Meeting in mid-May.

Paris-based AI-based medical imanging specialist AZmed SA has secured a €15min Series A financing led by Maison Worms, Techstars, and Tempact Ventures.

Bayer SE subsidiary Asklepios BioPharmaceutical Inc. (AskBio) has started Phase II testing of AB-1002 (NAN-101) in patients with congestive heart failure. 

German Green Elephant Biotech has launched the world’s first plant-based 96-well microtitre plate on the market.